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Abstract 
Objective: Lobular intraepithelial neoplasia (LIN) is a rare breast disease that has been 
regarded alternately as a risk factor for invasive breast cancer in both breasts or a true breast 
cancer precursor. The controversy is largely dependent on the estimation of the IBC (Invasive 
Breast Cancer) risk after LIN;  however a systematic review of the published data has not 
been previously performed. We aimed to review the IBC after LIN and the characteristics of 
those cancers. 
Methods: a PubMed search was performed to identify the published articles in English 
addressing the breast cancer risk after LIN.  
Results: There was a wide range in the figures estimating the risk of the breast cancer among 
the 22 studies that form the basis of this review. The cumulative average risk of invasive 
breast cancer (IBC) was 8.7% (range 0-33). It was 4.7% (range 0-25) for the ipsilateral and 
4.2% (range 0-16) for the contralateral breast. 52% of the breast cancers occurred more than 
10 years after the initial LIN. A lobular histotype was present in 30% (range 0 to 67%) of all 
IBC. 
Conclusions: LIN should be considered both as a risk factor (low and similar level of IBC risk 
for both breasts, long delay between LIN and IBC) and a precursor for IBC (over-
representation of lobular histotype). 
 
Keywords: lobular intraepithelial neoplasia, lobular carcinoma in situ, atypical lobular 
hyperplasia, breast cancer, review 
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Introduction 
Lobular intra-epithelial neoplasia (LIN), which comprises atypical lobular neoplasia and 
lobular carcinoma in situ, is a rare disease characterised by non invasive lobular breast 
proliferation [1].  
The incidence of LIN, has increased dramatically  in recent years, at least partly due to the 
widespread uptake of mammographic screening [2]. 
Since the first description of LIN in 1941 [3], its treatment has remained controversial; 
ranging from simple biopsy [4, 5, 6, 7] to ipsilateral mastectomy and contralateral biopsy [8], 
or even bilateral mastectomy [9]. The treatment choice has largely been dependent on the 
estimation of the invasive breast cancer risk and on whether LIN was considered as a marker 
of increased risk of cancer for both breasts (the “risk factor theory”) [10] or a true breast 
cancer precursor (the “precursor theory”) [11]. 
This review addresses the evaluation of the risk of invasive breast cancer (IBC) and ductal 
carcinoma in situ (DCIS) following a diagnosis of LIN. It also examines whether the 
characteristics of the cancers diagnosed following LIN favour “the risk factor” or “the 
precursor” theory. 
 
 
Methods 
A PubMed search was carried out on January 31, 2010. The search strategy consisted of terms 
“lobular intra-epithelial neoplasia”, “lobular carcinoma in situ”, “atypical lobular 
hyperplasia”, combined with “breast cancer”, “breast carcinoma”. The search was limited to 
articles published in English from 1969 to the search date and resulted in an output of 1761 
articles. The available abstracts were reviewed for relevance to the topic of breast cancer risk 
of original series of patients after LIN diagnosis. 
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Since LIN was in most cases an incidental finding, it was often associated with various benign 
breast disease conditions that had led to the breast biopsy. However patients were only 
included when LIN was considered the most risk-associated pathological finding. Patients 
with associated DCIS and invasive breast cancers were excluded. 
Where several articles referred to the same patient’s series, only the last publication was taken 
into account. The 22 articles which met these criteria form the basis of  this report. 
The publications of Chuba et al [10] and Li et al [12] referred both to the SEER (Surveillance, 
Epidemiology, and End Results Program) with an overlapping in inclusion dates (respectively 
1973 to 1998 and 1988 to 2002). The overlapping time frame  prevented us from using both 
studies in the risk estimations. For the estimations of breast cancer risk after LIN (Tables 1 
and 2) we chose to present as “Total 1” the results of all studies including Chuba et al but 
excluding Li et al, and as “Total 2” the results of all studies including Li et al but excluding 
Chuba et al. In the results and discussion sections we chose to refer to the results of all studies 
including Chuba et al and excluding Li et al, since the risk estimations are greater than those 
obtained with Li et al (except for the risk of ipsilateral IBC). 
 
Results 
Cumulative risk of breast cancer after LIN 
For a women diagnosed with LIN, the cumulative average risk of metachronous breast cancer 
(IBC or DCIS) was 9.6% (range 0-32). The average risk of IBC was 8.7% (range 0-33) 
whereas the average risk of DCIS was 2.9% (range 0-13) (Table 1).  
The average risk for IBC for the ipsilateral breast was 4.7% (range 0-25) which was (although 
slightly greater) near the level of risk for the contralateral breast that was 4.2% (range 0-16). 
The difference in risk between the two breasts was more pronounced  for the risk of DCIS that 
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was 2.3% (range 0-10) for the ipsilateral breast and 0.9% (range 0-4) for the contralateral 
breast (Table 2). 
Relative risk of invasive breast cancer after LIN 
To answer the question whether LIN modifies the IBC risk in a woman it is necessary to 
compare the observed IBC incidence in LIN patients with that of the general population. 
Table 3 summarizes the studies, which compared the risk of IBC in LIN patients to the risk of 
a referent population. Only studies with available 95% confidence intervals are reported. The 
relative risk was calculated by the ratio of the IBC rates observed in the LIN patients to the 
expected rates if IBC incidence was the same in LIN patients as it is in the population at large. 
The expected number of females developing IBC after LIN was calculated per year of 
diagnosis and age group [10, 13]. All studies were concordant to demonstrate an excess of 
IBC risk in LIN patients, with a relative risk ranging from 2.4 to 11.9. 
Modifiers of invasive breast cancer risk after LIN 
Various qualitative and quantitative pathological features were evaluated for association with 
IBC risk after LIN [4, 5, 7, 13, 14, 15, 16]. Higher IBC risk was only found to be associated 
with intense lymphocytic reaction in lobules with LIN [16], larger nuclear size [4], and 
pathological grade 3 or 2 according a three tired grading system [7].  
Age at LIN diagnosis also modified the IBC risk in the study by Bodian et al, with an 
increased risk for women younger than 40 years and a decreased risk for women older than 55 
years [13]. However this result was not confirmed in other studies [10, 12, 17, 18]. 
No association could be demonstrated between IBC risk after LIN and ethnicity, reproductive 
factors, or family history [10, 12, 13, 16]. 
Characteristics of invasive breast cancers after LIN 
Fifty-two percent of breast cancer (BC) occurred more than 10 years after the initial diagnosis 
of LIN was made (Table 4). Compared to ipsilateral BC, contralateral BC were more 
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frequently delayed. Contralateral BC were less frequent during the first five years and more 
frequent after 10 years. Compared to the general population the relative risk of IBC in the LIN 
patients was not dependent on the follow-up [10, 12, 13, 15, 17, 18]. The excess of risk was 
almost identical up to 20 years after the LIN diagnosis [10, 13, 17]. Beyond twenty years of 
follow-up there were too few patients to provide valid  estimations. 
A lobular histotype was present in 30% (range 0 to 67) of  all IBC recurrences  (Table 1). A 
lobular histotype was more frequent for ipsilateral IBC (51% range 0 -100) than for 
contralateral IBC (41% range 0 -60). 
The topography of ipsilateral IBC recurrences were only reported in 3 studies. In the study by  
Carson et al, one out of three recurrences were in the same quadrant as the initial LIN [19]. In 
the study by Cutuli et al [20], the sole ipsilateral recurrence was in the same quadrant as the 
initial LIN and in the series reported by Fisher et al, all the nine ipsilateral recurrences were in 
the same quadrant [7].  
 
Discussion 
In this review the cumulative average risk of metachronous IBC was 8.7% but with a wide 
variation from study to study, ranging from 0 to 33%. The risk was slightly greater for the 
ipsilateral as compared to the contralateral breast. Tumors characteristics supported arguments 
both for considering LIN as a non obligatory breast cancer precursor and as a risk factor for 
bilateral breast cancer. 
Before interpreting results of this study, it is important to acknowledge its limitations. Most of 
the follow-up studies of women with LIN are both small and retrospective. Studies have 
differed with respect to several factors including criteria for patient selection, length of 
follow-up, treatment of LIN and periods of inclusion (spanning from 1940 [21] to 2002 [12] ). 
Histological diagnoses were oftently made by community pathologists at different periods of 
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time, misclassification of histologic types is likely to have occurred. DCIS following LIN 
were inconsistently reported [14, 17, 10, 12], and in some series it was not possible to 
distinguish DCIS and IBC [13]. We only recorded metachronous breast cancers, however the 
definition differed slightly from study to study using the term metachronous to define breast 
cancers occurring either more than 6 or 12 months after the initial LIN diagnosis [7, 12]. 
Another limitation of the current study was the impossibility due to the study design to 
control for the confounding factors in the estimation of IBC risk, particularly the length of 
follow-up and the initial treatment of the LIN. 
However, the greatest limitation of the LIN series that  form the basis of our review is the 
rarity of the disease. In our study the estimations of IBC risk are based on more than 6000 
patients diagnosed with LIN. 
When Foote and Stewart described LIN it was viewed as a malignancy requiring a 
mastectomy [3]. However, retrospective studies of archived breast biopsy specimens 
originally read as benign and diagnosed as LIN on review showed that most women had not 
developed breast cancer even after long follow-up and that invasive breast cancer did not 
necessarily arise in the breast where the LIN was initially diagnosed [15]. This results were 
confirmed by series of patients treated with excisional biopsy alone. In those series the 20 
years cumulative risk was up to 33%, and women with LIN were equally likely to be 
diagnosed with ipsilateral and contralateral invasive breast cancers [14, 15, 16, 22]. The LIN 
was then considered as a marker of breast cancer risk. The only logical approaches under this 
“risk factor theory” were either a close follow-up or a bilateral mastectomy. However, 
bilateral mastectomy was unnecessary for the vast majority of patients, and this procedure 
never achieved great popularity even by the time when conservative procedures were 
developed for IBC [23]. 
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More recently the “precursor theory” has gained popularity since it was demonstrated that 
LIN and invasive lobular neoplasia share the lack of expression of the E-cadherin adhesion 
cell molecule. This latter finding suggests a possible transformation of LIN into invasive 
lobular neoplasia [11]. 
In our study the relatively low level of risk for invasive breast cancer and the time distribution 
of the recurrences with more than 50% of BC occurring more than 10 years after the initial 
LIN were in favour of the risk factor theory. Another major argument was the risk of invasive 
contralateral breast cancer that was near the level of risk for ipsilateral invasive breast cancer. 
Some authors have argued that contralateral breast cancers risk was explained by the frequent 
bilaterality of LN. However, similar levels of risk were observed in series were contralateral 
breast biopsies were systematically performed at the time of the LIN diagnosis [8]. Another 
argument for the “risk factor theory” was that the majority of IBC following LIN do not 
contain any invasive lobular histotype (Table 1). 
On the other hand some results of our study clearly advocate the precursor theory. Although 
the average level of IBC risk was low, there was a wide range in the risk between studies. The 
highest risks were observed in studies where no surgical procedure other than the initial 
excision biopsy were performed. It has been demonstrated that residual LIN was present in 
the majority of cases after excisional biopsy [24]. This results suggested that the removal of 
the initial LIN may be beneficial. As previously stated the risk of IBC for the ipsilateral breast 
was near the level observed for the contralateral breast. However, in most series it was 
slightly lower (Table 2). This could be in keeping with an evolution of the LIN into IBC in 
some women. Although not predominant, lobular invasive breast cancer was over represented 
in IBC recurrences since it was observed in 30% of cases, whereas it only represents 16% of 
IBC in the general population [1]. Moreover lobular invasive breast cancers were more 
frequent in the ipsilateral breast (51%) as compared to the contralateral (41%). Finally the 
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topography of the ipsilateral IBC recurrences brought another argument for the precursor 
theory since there were in most cases in the same quadrant as the initial LIN [7]. 
In this review LIN patients had a relative risk of IBC that was 2 to 4 folds that of the general 
population, except in the study of Andersen et al [17]. Since the majority of LIN patients will 
ultimately not develop an IBC, the identification of subgroups of patients at increased risk 
would be helpful to tailor the initial treatment. Studies that have attempted to identify IBC 
risk modifiers in LIN patients have however yielded either inconclusive or conflicting results. 
An exception is exemplified by the pathological grading system proposed by Fisher et al [7], 
which however requires confirmation in further studies. 
 
Conclusions 
This review of the current data on LIN  presents strong arguments for LIN both as a precursor 
and a risk factor for IBC. In the author’s opinion, consideration of the precursor argument  
makes it logical to attempt to remove the LIN. However, the risk factor aspect with a low 
level of risk and a risk for contralateral breast cancer argue in our opinion for a lumpectomy 
rather than a mastectomy, and a close follow-up. Further evaluations are required to evaluate 
the potential benefit of the removal of the LIN, the role of free margins, and to identify IBC 
risk modifiers among LIN patients.  
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Table 1: Risk of metachrone breast cancer after lobular intraepithelial neoplasia (LIN) 
 
Author, year Follow-
up 
(years) 
LIN 
 
Ipsilateral 
mastectomy 
N (%) 
Women 
with 
recurrence 
(inv + 
DCIS) N 
(%) 
DCIS 
N(%) 
Invasive 
breast cancer 
N (%) 
Invasive 
lobular  N 
(%) 
Hutter, 1969 [21] 4-27** 46 6 (13) 15 (32) 6 (13) 14 (30) - 
Wheeler, 1974 
[14] 
16§ 38 13 (34) 4 (11) - 4 (11) 1 (25) 
Andersen, 1977 
[17] 
16§ 47 3 (6) 10 (21) - 12 (26) - 
Haagensen, 1978 
[15] 
14§ 211 18 (9) 36 (17) 9 (4) 30 (14) 19 (63) 
Rosen, 1978 [16] 24§ 99 0 (0) 32 (32) 2 (2) 33 (33) 13 (39) 
Curletti 1981 [25] 7-21** 19 0 (0) 2 (11) - 2 (11) - 
Rosen, 1981 [8] 15§ 101 84 (84) 8 (8) 1 (1) 7 (7) 1 (14) 
Sunshine, 1985 
[26] 
12 min 36 33 (92) 0 0 0 0 
Ringberg, 1991 
[27] 
8* 33 22 (67) 1 (3) 0 1 (3) 0 
Graham, 1991 [28] 6§ 20 0 (0) 1 (5) 0 1 (5) 0 
Ciatto, 1992 [29] 5§ 60 23 (38) 6 (10) 1 (2) 5 (8) - 
Carson, 1994 [19] 7* 60 9 (15) 3 (5) 2 (3) 3 (5) 2 (67) 
Zurrida, 1996 [30] 4* 157 22 (14) 10 (6) 0 (0) 10 (6) 4 (40) 
Bodian, 1996 [13] 18* 234 20 (9) 62 (26) - - 12/45 (27) 
Ottesen, 2000 [4] 12* 100 0 (0) 18 (18) 5 (5) 13 (13) 3 (23) 
Goldstein, 2001 
[5] 
22§ 82 0 (0) 16 (20) 1 (1) 20 (24) 11 (55) 
Page, 2003 [6] 18-53** 161 0 (0) 25 (16) - 26 (16) - 
Fisher, 2004 [7] 17 min 180 0 (0) 26 (14) 10 (6) 19 (10) 14 (74) 
Levi, 2005 [18] 3-28** 88 - 8 (9) - 8 (9) - 
Cutuli, 2005 [20] 13* 25 0 (0) 2 (8) 0 (0) 2 (8) 0 (0) 
Chuba,  2005 [10] 7-31** 4853 1281/4600 
(28) 
350/4853 
(7) 
- 350/4853 (7) 81/350 
(23) 
Li, 2006 [12] 3-17** 4490 - 282 (6) - 282/4490 (6) 119/242 
(49) 
Total 1 (with 
Chuba and without 
Li) 
 6650 1534/6397 
24% 
635/6650 
9.6% 
37/1270 
2.9% 
560/6416 
8.7% 
161/538 
30% 
Total 2 (with Li 
and without 
Chuba) 
 6287 253/1797 
14% 
567/6287 
9% 
37/1270 
2.9% 
492/6053 
8.1% 
199/430 
46% 
 
Legend :  
-Since the study of Chuba et al, and Li et al al referred both to the same population with an 
overlapping in inclusion dates the Total 1 involves all studies except Li et al and the Total 2 
involves all studies except Chuba et al. 
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-Expression of follow-up*median, §mean, **minimal and maximal follow-up 
-In the study of Sunshine one patient died from metastases after ipsilateral mastectomy 
without contralateral breast cancer. 
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Table 2: Risk of ipsilateral and contralateral metachrone breast cancer after lobular 
intraepithelial neoplasia (LIN)  
 
Ipsilateral breast cancer Contralateral breast cancer Author, year Follow-
up 
(years) 
Wom
en at 
risk 
DCIS Invasive 
rec N(%) 
Invasive 
lobular 
N(%) 
Women 
at risk 
DCIS Invasive 
rec N(%) 
Invasive 
lobular 
N(%) 
Hutter, 1969 
[21] 
4-27 40 4 (10) 10 (25) - 46 2 (4) 4 (9) - 
Wheeler, 1974 
[14] 
16§ 25 - 1 (4) 1 (100) 32 - 3 (9) 0 (0) 
Andersen, 1977 
[17] 
16§ 44 - 8 (18) - 47 - 4 (9) - 
Haagensen, 1978 
[15] 
14§ 193 - - - 205 - - - 
Rosen, 1978 [16] 24§ 99 1 (1) 17 (17) 8 (47) 99 1 (1) 16 (16) 5 (31) 
Rosen, 1981 [8] 15§ 17 0 (0) 2 (12) 1 (50) 101 1 (1) 5 (5) 0 (0) 
Sunshine, 1985 
[26] 
12 min 3 0 0 0 15 0 0 0 
Ringberg, 1991 
[27] 
8* 11 0 1 (9) 0 15 0 0 0 
Graham, 1991 
[28] 
6§ 20 0 1 (5) 0 20 0 0 0 
Ciatto, 1992 [29] 5§ 37 0 (0) 4 (11) 2 (50) 60 1 (2) 1 (2) - 
Carson, 1994 
[19] 
7* 51 1 (2) 3 (6) 2 (75) 60 1 (2) 0 (0) 0 (0) 
Zurrida, 1996 
[30] 
4* 135 0 (0) 4 (3) 2 (50) 157 0 (0) 6 (4) 2 (33) 
Ottesen, 2000 
[4] 
12* 100 5 (5) 11 (11) 3 (27) 100 0 (0) 2 (2) 0 (0) 
Goldstein, 2001 
[5] 
22§ 82 1 (1) 13 (16) 7 (54) 82 0 (0) 7 (9) 4 (57) 
Page, 2003 [6] 18-53 161 - 18 (11) - 161 - 6 (4) - 
Fisher, 2004 [7] 17 min 180 7 (4) 9 (5) 8 (89) 180 3 (2) 10 (6) 6 (60) 
Cutuli, 2005 [20] 13* 25 0 (0) 1 (4) 0 (0) 25 0 (0) 1 (4) 0 (0) 
Chuba, 2005 
[10] 
7-31 3141 - 93 (3) - 4422 - 171/4420 
(4) 
- 
Li, 2006 [12] 3-17** 4490 - 165 4) - 4490 - 116/4490 
(2.6) 
- 
Total 1 (with 
Chuba and 
without Li) 
 4364 19/800 
2.3% 
196/4171 
4.7% 
 
34/67 
51% 
5827 9/960 
0.9% 
236/5620 
4.2% 
17/41 
41% 
Total 2 (with Li 
and without 
Chuba 
 5713 19/800 
2.3% 
268/5520 
4.9% 
34/67 
51% 
5895 9/960 
0.9% 
181/5960 
3.0% 
17/41 
41% 
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Legend :  
-Since the study of Chuba et al, and Li et al al referred both to the same population with an 
overlapping in inclusion dates the Total 1 involves all studies except Li et al and the Total 2 
involves all studies except Chuba et al. 
-Expression of follow-up:*median, §mean, **minimal and maximal follow-up 
-“Women at risk” for the ipsilateral breast, or for the contralateral breast, are women who at 
the time of LIN diagnosis had no mastectomy of the ipsilateral breast or of the contralateral 
breast, respectively. 
-rec: recurrence  
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Table 3: Relative risk of invasive breast cancer  (IBC) after lobular intraepithelial neoplasia 
(LIN) 
 
 
 
 
author, year number of 
observed IBC 
number of 
expected IBC 
Ratio observed to 
expected 
95% confident 
interval 
Andersen, 1977 
[17] 
Page, 2003 [6] 
Levi, 2005 [18] 
Chuba, 2005 [10] 
11 
- 
8 
- 
0.9 
- 
1.7 
- 
11.9* 
2.6** 
4.2§ 
2.4§ 
6.3 - 19.2 
1.7 – 3.9 
2.1 – 7.5 
2.1 – 2.3 
 
 
Legend: The ratio observed to expected (number of IBC observed in the study group of 
women with a past history of LIN to the number of IBC expected in this group on the basis of 
incidence rates in the general population) was expressed either as the Relative Risk (*), the 
hazard ratio (**) or the Standardized Incidence Ratio (§), according to the study design. 
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Table 4. Time interval until subsequent carcinoma after lobular intraepithelial neoplasia (LIN) 
 
Overall cancers Ipsilateral cancers Contralateral cancers Author, 
year N 1 to 
≤5 yrs 
6 to 
≤10 
yrs 
>10 
yrs 
N 1 to 
≤5 yrs 
6 to 
≤10 
yrs 
>10 
yrs 
N 1 to 
≤5 yrs 
6 to 
≤10 
yrs 
>10 
yrs 
Hutter, 
1969 [21] 
20 6  4 10  14 5 2 7 6 1 2 3 
Wheeler, 
1974 [14] 
4 0  2  2  1 0 0 1 3 0 2 1 
Andersen, 
1977 [17] 
12 3  3  6  8 3 1 4 4 0 2 2 
Haagensen, 
1978 [15] 
35 15  6  14  19 6 5 8 16 9 1 6 
Rosen, 
1978 [16] 
35 3  7  25  19 2 3 14 16 1 4 11 
Ringberg, 
1991 [27] 
1 1 0 0 1 1 0 0 0 0 0 0 
Graham, 
1991 [28] 
1 1 0 0 1 1 0 0 0 0 0 0 
Ciatto, 
1992 [29] 
- - - - 4 3 1 0 - - - - 
Carson, 
1994 [19] 
3 2  1  0  3 2 1 0 0 0 0 0 
Zurrida, 
1996 [30] 
10 5   5  0  4 3 1 0 6 2 4 0 
Bodian, 
1996 [13] 
62 10  19 33 - - - - - - - - 
Goldstein, 
2001 [5] 
21 2  5  14  - - - - - - - - 
Fisher, 
2004 [7] 
19 8 7 4 9 5 4 0 10 3 3 4 
Cutuli, 
2005 [20] 
2 1 0 1 1 0 0 1 1 1 0 0 
Chuba, 
2005 [10] 
265 34 83 148 99 13 34 52 166 21 49 96 
Total  490 91 
(19%) 
144 
(29%) 
257 
(52%) 
183 44 
(24%) 
52 
(28%) 
87 
(48%) 
228 38 
(17%) 
67 
(29%) 
123 
(54%) 
 
 
 
 
 
 
